Peptide Monograph

Semax

Synthetic ACTH(4-10) Analog with Pro-Gly-Pro Extension

At a Glance

Mechanism of Action

Semax is a synthetic heptapeptide analog of the adrenocorticotropic hormone (ACTH) fragment 4-10 (Met-Glu-His-Phe-Pro-Gly-Pro). The native ACTH(4-10) fragment was identified as the minimal sequence retaining the neurotrophic and cognitive-enhancing properties of ACTH, independent of its adrenal steroidogenic activity. Semax incorporates a C-terminal Pro-Gly-Pro tripeptide extension, identical to the stabilizing modification used in Selank, which dramatically increases metabolic stability and prolongs biological activity.[1]

A defining feature of Semax's pharmacology is that it does not possess the adrenal-stimulating effects of full-length ACTH. The ACTH(4-10) fragment does not bind to the MC2R (melanocortin 2 receptor), which mediates cortisol release from the adrenal cortex. This means that Semax provides the neurotrophic benefits of the ACTH signaling fragment without causing cortisol elevation, adrenal hypertrophy, or hypothalamic-pituitary-adrenal axis disruption.[1][2]

Semax's primary mechanism involves robust upregulation of neurotrophins. Eremin et al. demonstrated that Semax significantly increases the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the rat brain, particularly in the hippocampus, basal forebrain, and cerebral cortex. This neurotrophin upregulation is considered the central mechanism underlying both its nootropic and neuroprotective effects.[3]

The peptide also modulates monoamine neurotransmission, influencing dopaminergic and serotonergic systems. Dolotov et al. showed that Semax affects dopamine turnover and serotonin metabolism in brain regions critical for cognition, attention, and executive function. This monoaminergic modulation likely contributes to the attention-enhancing and alertness-promoting effects reported by users.[4]

In the context of ischemic brain injury, Semax provides neuroprotection through multiple converging mechanisms: neurotrophin-mediated neuronal survival, anti-inflammatory effects (reduction of pro-inflammatory cytokines and microglial activation), and modulation of the expression of genes involved in apoptosis and oxidative stress. Levitskaya et al. demonstrated that Semax improves neurological outcomes in experimental stroke models and accelerates functional recovery.[5]

Additionally, Semax has demonstrated effects on gene expression in the CNS, modulating the transcription of hundreds of genes involved in neurotransmission, immune response, vascular function, and neuroplasticity. This broad transcriptomic effect suggests a pleiotropic mechanism that extends beyond simple receptor agonism.[3]

Evidence Summary

Russian Clinical Experience

Semax has been used clinically in Russia since the 1990s for several neurological indications. Ashmarin et al. conducted foundational studies demonstrating cognitive enhancement in both healthy volunteers and patients with cognitive impairment, with improvements in attention, memory consolidation, and learning efficiency. These studies formed part of the evidence base for Russian regulatory approval.[2]

In the context of stroke, Semax (1% nasal solution) has been used as an adjunctive neuroprotective therapy in Russian clinical practice. Clinical studies reported improved neurological outcomes when Semax was administered in the acute and subacute phases of ischemic stroke, including faster recovery of motor function and reduced disability scores compared to standard care alone.[5]

Semax has also been investigated and used clinically in Russia for optic nerve disease, including optic neuritis and glaucoma-related optic neuropathy, based on its neurotrophin-mediated neuroprotective effects. Russian ophthalmological studies reported preservation of visual function with intranasal Semax treatment.[2]

Preclinical and Mechanistic Studies

Eremin et al. provided critical mechanistic evidence by demonstrating that Semax significantly upregulates BDNF and NGF mRNA and protein expression in rat brain tissue. The magnitude of BDNF upregulation was substantial and persisted for hours after administration, providing a molecular basis for the observed neuroprotective and cognitive-enhancing effects.[3]

Dolotov et al. further characterized Semax's neurochemical effects, showing modulation of dopamine and serotonin metabolism and demonstrating that the peptide affects the expression of genes involved in neurotransmitter synthesis and receptor signaling. These findings support a mechanism of action that involves coordinated modulation of multiple neurotransmitter systems rather than action at a single target.[4]

Primary Uses

Based on the available clinical and preclinical literature, Semax has been investigated and used for the following applications:

• Cognitive enhancement (nootropic) — The primary use in both Russian clinical practice and the global nootropic community. Improvements in attention, memory, learning, and mental clarity attributed to BDNF/NGF upregulation and monoamine modulation.[2]
• Stroke recovery (neuroprotection) — Used in Russian hospitals as adjunctive therapy in acute and subacute ischemic stroke. The 1% nasal solution (higher concentration) is used for this indication.[5]
• Traumatic brain injury — Investigated in Russian clinical settings for neuroprotection and recovery support following TBI. Based on the same neurotrophin-mediated neuroprotective mechanism as stroke therapy.[5]
• Optic nerve disease — Used in Russian ophthalmological practice for optic neuritis, glaucoma-related optic neuropathy, and other conditions involving optic nerve degeneration.[2]
• Attention deficit and cognitive decline — Investigated for age-related cognitive decline and attention disorders based on its dopaminergic modulation and neurotrophin-enhancing properties.[4]

Contraindications

Standard Protocols

Note on variants: N-Acetyl Semax Amidate (NASA) is a modified form of Semax with N-terminal acetylation and C-terminal amidation, which reportedly enhances stability and bioavailability. This variant is popular in the nootropic community but has not been the subject of formal clinical trials. Dosing is typically lower than standard Semax due to the assumed greater potency.

The 0.1% Russian pharmaceutical formulation is used for cognitive enhancement and mild neurological conditions, while the 1% formulation is reserved for acute neurological emergencies (stroke, TBI) and is used in hospital settings.

Common Stacks & Synergies

In the nootropic and peptide research community, Semax is frequently combined with other compounds. The following stacks are commonly discussed but have no published clinical evidence supporting their combined use:

• Semax + Selank — The most commonly reported combination. The rationale is that Semax's stimulatory and dopaminergic profile complements Selank's anxiolytic and GABAergic effects, creating a balanced nootropic stack with both cognitive enhancement and anxiety reduction. Both peptides share the Pro-Gly-Pro stabilizing extension and originate from the same Russian research program.
• Semax + NA-Semax Amidate — Some users alternate between standard Semax and the N-Acetyl Amidate variant, or use the modified version exclusively for its reportedly enhanced potency and duration of action.
• Semax + racetams (e.g., piracetam, phenylpiracetam) — Combining Semax with racetam-class nootropics is common in the nootropic community, based on the rationale of complementary cognitive-enhancing mechanisms.
• Semax + choline sources (e.g., alpha-GPC, CDP-choline) — Choline supplementation is a common adjunct to nootropic stacks, providing substrate for acetylcholine synthesis.

Preparation & Administration

Semax is available in two primary forms: as the approved Russian pharmaceutical nasal spray (0.1% and 1% solutions) and as lyophilized (freeze-dried) powder from research chemical suppliers.

Intranasal (Pharmaceutical Product)

The Russian pharmaceutical formulations are Semax 0.1% (for cognitive enhancement and mild neurological conditions) and Semax 1% (for acute stroke and neuroprotection). The 0.1% solution delivers approximately 50 mcg per drop, with a standard dose of 2–3 drops per nostril (200–300 mcg per administration). The solution should be at room temperature before use. Tilt the head slightly back during administration to facilitate mucosal absorption.

Intranasal (Reconstituted)

Lyophilized Semax can be reconstituted with bacteriostatic water and administered intranasally using a nasal spray bottle designed for peptide delivery. For a 5 mg vial reconstituted with 2.5 mL of bacteriostatic water, the concentration is 2 mg/mL (200 mcg per 0.1 mL). Typical nasal spray bottles deliver approximately 0.1 mL per actuation.

General Administration Notes

Semax is administered almost exclusively via the intranasal route, as this provides direct access to the CNS through the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier. Morning and early afternoon dosing is generally preferred due to the stimulatory profile, which may interfere with sleep if administered late in the day. For detailed reconstitution instructions, see the Reconstitution Guide.

Side Effects & Adverse Events

In Russian clinical studies and post-marketing surveillance, Semax has been reported to be generally well tolerated across both the 0.1% and 1% formulations. The favorable safety profile was a significant factor in its regulatory approval for clinical use in Russia.[2]

Reported side effects:

• Nasal irritation — The most commonly reported adverse effect. Mild stinging, burning, or dryness in the nasal mucosa, typically transient and more common with the 1% formulation.
• Headache — Mild headaches reported occasionally, more common at higher doses. Generally self-limiting.
• Irritability at higher doses — Some users report increased irritability, restlessness, or overstimulation at higher doses, consistent with Semax's stimulatory neurochemical profile. Dose reduction typically resolves this effect.[4]
• Insomnia — Difficulty sleeping if Semax is administered too late in the day. This is related to the stimulatory and dopaminergic effects and is generally avoided by restricting dosing to morning and early afternoon.

Importantly, Semax does not produce the adrenal side effects associated with full-length ACTH (cortisol elevation, adrenal hyperplasia, metabolic disruption), as the ACTH(4-10) fragment lacks MC2R affinity. No physical dependence, tolerance, or withdrawal syndrome has been reported with Semax use in Russian clinical practice.[1]

Drug Interactions

No formal drug interaction studies meeting Western standards have been conducted with Semax. The following theoretical interactions are based on the peptide's known pharmacological mechanisms:

• Dopaminergic agents (L-DOPA, dopamine agonists, antipsychotics) — Semax modulates dopaminergic neurotransmission. Concurrent use with dopamine agonists could produce additive effects, while dopamine antagonists (antipsychotics) could attenuate Semax's cognitive effects or produce unpredictable interactions.[4]
• SSRIs and SNRIs — Semax influences serotonin metabolism in the CNS. Theoretical interactions with serotonergic antidepressants are possible, though the risk of serotonin syndrome appears low given Semax's modulatory mechanism.[4]
• Stimulants (amphetamine, methylphenidate, modafinil) — Semax's stimulatory profile (dopaminergic modulation, increased alertness) could produce additive effects when combined with CNS stimulants, potentially increasing the risk of overstimulation, anxiety, or cardiovascular effects.
• Corticosteroids and HPA-axis modulators — Although Semax does not directly affect cortisol levels, its ACTH-derived structure suggests caution with concurrent corticosteroid therapy, as complex neuroendocrine interactions are theoretically possible.[1]

Storage & Handling

Do not freeze reconstituted solution. Protect from prolonged light exposure. Semax is a short peptide and may be somewhat less stable in solution than larger peptides. If the solution appears cloudy, discolored, or contains particulate matter, discard. For nasal administration, ensure the spray device is clean and does not become contaminated. The methionine residue at position 1 is susceptible to oxidation; protect from oxygen exposure.

Legal & Regulatory Status

• Russia and CIS — Approved as a nootropic and neuroprotective medication. Available as pharmaceutical nasal drops in 0.1% concentration (cognitive enhancement) and 1% concentration (stroke and neuroprotection). Prescribed for stroke recovery, cognitive impairment, optic nerve disease, and related neurological conditions.
• FDA (United States) — Not approved for any indication. Not scheduled as a controlled substance. Available as a research chemical. Not recognized as a dietary supplement.
• European Union — Not approved as a medicinal product by the EMA. Available as a research chemical in most member states. Not scheduled.
• United Kingdom — Not approved by the MHRA. Available as a research chemical. Not scheduled under the Misuse of Drugs Act.
• WADA — Not currently specifically listed on the WADA Prohibited List, though it could potentially fall under non-approved substance categories depending on interpretation.

Open Questions

Significant gaps remain in the Semax evidence base, particularly for Western clinical practice:

• Absence of Western clinical trials — No randomized controlled trials meeting FDA or EMA standards have been conducted. The quality and generalizability of Russian clinical data is difficult to independently assess. This is the most significant limitation for Western clinical adoption.
• Stroke neuroprotection efficacy — While Russian clinical experience is extensive, the neuroprotective efficacy of Semax in acute stroke has not been validated in Western multicenter RCTs. Given the enormous clinical need, this represents a significant research opportunity.
• Comparative efficacy for cognition — Head-to-head comparisons with established nootropics, cognitive enhancers, or cholinesterase inhibitors in rigorously designed trials have not been published.
• N-Acetyl Semax Amidate pharmacology — This popular variant has no published clinical or rigorous preclinical data. Its pharmacokinetics, pharmacodynamics, and safety profile relative to standard Semax are unknown.
• Long-term neurotrophin upregulation — The consequences of chronically elevated BDNF and NGF levels from repeated Semax courses are not well characterized. While neurotrophins are generally neuroprotective, excessive neurotrophin signaling could theoretically have adverse effects.
• Product quality from research chemical sources — Outside of Russia, Semax is available only from unregulated research chemical suppliers. Purity, sterility, and accurate labeling cannot be guaranteed.

Bibliography

1. Ashmarin IP, Nezavibatko VN, Levitskaya NG, Koshelev VB, Kamensky AA. "Design and investigation of an ACTH(4-10) analogue lacking D-amino acids and possessing nootropic properties." Neurosci Res Commun. 1995;16(2):105-112. doi:10.1002/nrc.680160207.
2. Ashmarin IP, Samonina GE, Lyapina LA, Kamenskii AA, Levitskaya NG, Grivennikov IA, Dolotov OV, Andreeva LA. "Natural and hybrid ("chimeric") stable regulatory glyproline peptides." Pathophysiology. 2005;11(4):179-185. doi:10.1016/j.pathophys.2004.10.001. PMID:15837230.
3. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. "Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents." Neurochem Res. 2005;30(12):1493-500. doi:10.1007/s11064-005-8826-8. PMID:16362768.
4. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Grivennikov IA, Myasoedov NF. "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." Brain Res. 2006;1117(1):54-60. doi:10.1016/j.brainres.2006.07.108. PMID:16996037.
5. Levitskaya NG, Sebentsova EA, Andreeva LA, Alfeeva LY, Kamenskii AA, Myasoedov NF. "The neuroprotective effects of Semax in conditions of acute hypoxia." Dokl Biol Sci. 2004;399(1-6):424-6. doi:10.1007/s10630-005-0011-0. PMID:15648282.